Antibiotic Administration Guidelines

Introduction to Meropenem Administration

The American College of Critical Care Medicine recommends administering meropenem via extended infusion (3-4 hours) or continuous infusion rather than standard bolus injection to optimize pharmacodynamic efficacy, especially for severe infections or when treating bacteria with high MICs 1
For optimal bactericidal activity, β-lactam concentrations should remain above the MIC for at least 70% of the dosing interval, with a target of 4-6 times the MIC for severe infections 1
The World Journal of Emergency Surgery recommends meropenem 1g q6h by extended infusion or continuous infusion 2
For patients with suspected MDR pathogens, consider meropenem/vaborbactam 2g/2g q8h by extended or continuous infusion 2

Administering a loading dose followed by continuous infusion of the daily dose is particularly beneficial for critically ill patients, infections with bacteria having high MICs, deep-seated infections, and patients with altered pharmacokinetics 1
Always administer a loading dose before starting continuous infusion to rapidly achieve therapeutic concentrations 3
Target steady-state concentration of approximately 20 mg/L for continuous infusion 1
Consider therapeutic drug monitoring in critically ill patients, patients undergoing renal replacement therapy, and patients with clinical signs of toxicity 3
The Infectious Diseases Society of America recommends using the minimum effective dose to achieve therapeutic targets 4
For treatment of serious infections such as meningitis or ESBL-producing organisms, 2g every 8 hours is considered the maximum dose even for normal-weight adults 4
For critically ill patients, a dosage of 1 gram every 8 hours is recommended, as suggested by the World Journal of Emergency Surgery 5

6, 7, 8, 9

For patients over 59 years old with compromised renal function, consider reducing the dose of meropenem to 10 mg/kg (600 mg), as recommended by the American Thoracic Society 7

For intra-abdominal infections with adequate source control, the World Journal of Emergency Surgery recommends a treatment duration of 4-7 days 6
The typical duration of therapy for urosepsis is 7-14 days, but consider shorter duration (5-7 days) if rapid clinical improvement occurs, as recommended by the Society of Critical Care Medicine and the Infectious Diseases Society of America 10, 11
Treatment can be discontinued when the patient is afebrile for 48 hours, clinical stability is achieved, source control has been achieved, and the appropriate total duration for the specific infection has been completed, as recommended by the American Thoracic Society 8
Monitor renal function regularly during therapy and assess clinical response (temperature, heart rate, blood pressure, respiratory rate), as recommended by the Society of Critical Care Medicine 10
Consider therapeutic drug monitoring in critically ill patients if available, as recommended by the Society of Critical Care Medicine 10

For carbapenem-resistant Enterobacterales (CRE), meropenem may be used as part of combination therapy with polymyxins or other active agents, as recommended by the European Society of Clinical Microbiology and Infectious Diseases 12
High-dose extended-infusion meropenem-polymyxin combination therapy may be beneficial for CRE infections, particularly with KPC-producing K. pneumoniae, according to the guidelines from the Infectious Diseases Society of America 12
The World Health Organization recommends basing treatment on antimicrobial susceptibility testing to guide therapy 12
The Centers for Disease Control and Prevention recommend considering infectious disease consultation for severe infections with limited options and using combination therapy for highly resistant strains 12

For susceptible Enterobacteriaceae, fluoroquinolones (e.g., ciprofloxacin, levofloxacin) are recommended as an oral therapy option, according to the Intensive Care Medicine guidelines 1
For mixed infections, amoxicillin-clavulanate plus ciprofloxacin is suggested as an oral therapy option, based on research published in Clinical Infectious Diseases 13
The Infectious Diseases Society of America recommends fluoroquinolones, such as ciprofloxacin and levofloxacin, for patients with susceptible Klebsiella infections 12
The Society of Healthcare Epidemiology of America recommends amoxicillin-clavulanate for susceptible strains and trimethoprim-sulfamethoxazole for susceptible urinary tract infections 12

Carbapenems have limited stability at room temperature, with meropenem stable for 6-12 hours depending on concentration and imipenem stable for 2-3 hours 3
Meropenem is a carbapenem antibiotic used as a last-resort treatment for serious bacterial infections, with limitations on developing an effective oral formulation due to poor gut stability, limited intestinal absorption, and rapid renal elimination, as recommended by the American College of Clinical Pharmacology 1